TEVA - FDA rejects Viatris/Mapi long-acting version of Teva's Copaxone
2024-03-11 09:43:30 ET
More on Viatris
- Up 25%, I Still Believe 4%-Yielding Viatris Is Up To 60% Undervalued
- Viatris Inc. (VTRS) Q4 2023 Earnings Call Transcript
- Viatris Reduces Debt But Faces Growth Hurdles
- Dividend rally: Top 10 large-cap performers in 2024 with at least a 3% yield
- Viatris sets 2024 guidance above consensus; boosts share buybacks